Wall Street Zen Downgrades Polyrizon (NASDAQ:PLRZ) to Sell

Polyrizon (NASDAQ:PLRZ) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings lowered Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Polyrizon Stock Performance

PLRZ opened at $11.03 on Friday. The stock has a 50-day moving average of $12.25 and a 200-day moving average of $12.99. Polyrizon has a 52-week low of $2.88 and a 52-week high of $18.20.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC purchased a new stake in shares of Polyrizon Ltd. (NASDAQ:PLRZ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned 1.35% of Polyrizon at the end of the most recent reporting period.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.